Gerardo Villarreal1, Mark B Hamner1, Clifford Qualls1, José M Cañive1. 1. Dr. Villarreal, Behavioral Health Care Line (BHCL), Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, and Departments of Psychiatry and Neurosciences, University of New Mexico School of Medicine, New Mexico. Dr. Hamner, MD, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Charleston, S.C. Dr. Cañive, Departments of Psychiatry and Neurosciences, University of New Mexico School of Medicine, New Mexico. Dr. Qualls, Biomedical Research Institute of New Mexico and Department of Mathematics and Statistics, University of New Mexico, New Mexico.
Abstract
Objectives: A previous randomized placebo-controlled trial in military veterans posttraumatic stress disorder (PTSD) found that quetiapine improved global PTSD symptoms severity, depression and anxiety as well as the re-experiencing and hypearousal clusters. However, it is not known if individual symptoms had a preferential response to this medication. The goal of this study was to analyze the individual symptom response in this group of patients. Methods: Data from a previous trial was re-analyzed. Each of the of the scale items was analyzed individually using Repeated Measures Analysis of Variance. Results: Compared to placebo, there was a significant decline in the Clinician-Administered PTSD Scale intrusive memories and insomnia questions. In the Davidson Trauma Scale, greater improvements were observed on irritability, difficulty concentrating, hyperstartle and a trend was observed on avoiding thoughts or feelings about the event. Greater improvements compared with placebo were noted on the Hamilton Depression (HAM-D) middle and late insomnia items. On the Hamilton Anxiety scale (HAM-A), the insomnia item was significantly improved. Conclusions: Quetiapine demonstrated greater effect than placebo on several symptoms. The strongest response was seen on insomnia, which the highest significance level on the CAPS. The insomnia items of both the HAM-D and HAM-A also demonstrated improvement with quetiapine. These finding indicate quetiapine improved sleep measure. Insomnia can be a difficult problem to treat in PTSD patients, therefore quetiapine should be considered in difficult cases.
RCT Entities:
Objectives: A previous randomized placebo-controlled trial in military veterans posttraumatic stress disorder (PTSD) found that quetiapine improved global PTSD symptoms severity, depression and anxiety as well as the re-experiencing and hypearousal clusters. However, it is not known if individual symptoms had a preferential response to this medication. The goal of this study was to analyze the individual symptom response in this group of patients. Methods: Data from a previous trial was re-analyzed. Each of the of the scale items was analyzed individually using Repeated Measures Analysis of Variance. Results: Compared to placebo, there was a significant decline in the Clinician-Administered PTSD Scale intrusive memories and insomnia questions. In the Davidson Trauma Scale, greater improvements were observed on irritability, difficulty concentrating, hyperstartle and a trend was observed on avoiding thoughts or feelings about the event. Greater improvements compared with placebo were noted on the Hamilton Depression (HAM-D) middle and late insomnia items. On the Hamilton Anxiety scale (HAM-A), the insomnia item was significantly improved. Conclusions: Quetiapine demonstrated greater effect than placebo on several symptoms. The strongest response was seen on insomnia, which the highest significance level on the CAPS. The insomnia items of both the HAM-D and HAM-A also demonstrated improvement with quetiapine. These finding indicate quetiapine improved sleep measure. Insomnia can be a difficult problem to treat in PTSDpatients, therefore quetiapine should be considered in difficult cases.
Authors: Charles W Hoge; Carl A Castro; Stephen C Messer; Dennis McGurk; Dave I Cotting; Robert L Koffman Journal: N Engl J Med Date: 2004-07-01 Impact factor: 91.245
Authors: Jonathan Davidson; David Baldwin; Dan J Stein; Enrique Kuper; Isma Benattia; Saeed Ahmed; Ron Pedersen; Jeff Musgnung Journal: Arch Gen Psychiatry Date: 2006-10
Authors: Joseph Zohar; Daniela Amital; Chanoch Miodownik; Moshe Kotler; Avi Bleich; Roger M Lane; Carol Austin Journal: J Clin Psychopharmacol Date: 2002-04 Impact factor: 3.153
Authors: M I Butterfield; M E Becker; K M Connor; S Sutherland; L E Churchill; J R Davidson Journal: Int Clin Psychopharmacol Date: 2001-07 Impact factor: 1.659
Authors: Quinn M Biggs; Robert J Ursano; Jing Wang; Gary H Wynn; Russell B Carr; Carol S Fullerton Journal: BMC Psychiatry Date: 2020-04-16 Impact factor: 3.630